Request for Information Regarding Patient-Reported Outcome Measures, 8674-8675 [2018-04050]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
8674
Federal Register / Vol. 83, No. 40 / Wednesday, February 28, 2018 / Notices
or benefits of any product are
scientifically or clinically proven or
about the existence, contents, validity,
results, conclusions, or interpretations
of any test, study, or research.
Provision IV is a provision for FDAapproved claims.
Provision V prohibits
misrepresentations in connection with
the marketing, advertising, or promoting
of any product, service, or program that
paid commercial advertising is
independent programming.
Provision VI prohibits any
representation about any user,
consumer, or endorser of a covered
product without disclosing, clearly and
conspicuously, and in close proximity
to that representation, any unexpected
material connection between such
endorser and (1) any respondent; or (2)
any other individual or entity affiliated
with the product. ‘‘Unexpected material
connection’’ means any relationship
that might materially affect the weight
or credibility of the testimonial or
endorsement and that would not
reasonably be expected by consumers.
Provision VII prohibits
misrepresentations regarding the status
of any endorser or person providing a
review of a product, including a
misrepresentation that the endorser or
reviewer is an independent or ordinary
user of the product.
Provision VIII prohibits respondents
from providing the means and
instrumentalities to make any false or
misleading statement of material fact,
including the representations prohibited
by Provisions I to III. ‘‘Means and
instrumentalities’’ mean any
information, document, or article
referring or relating to any covered
product, including any advertising,
labeling, promotional, or purported
substantiation materials, for use by a
licensee to market or sell any covered
product.
Provision IX, triggered when the
human clinical testing requirement in
Provisions I or II applies, requires that
respondents secure and preserve all
underlying or supporting data and
documents generally accepted by
experts in the field as relevant to an
assessment of the test, such as protocols,
instructions, participant-specific data,
statistical analyses, and contracts with
the test’s researchers. There is an
exception for a reliably reported test
(defined as a test that is published in a
peer-reviewed journal) that was not
conducted, controlled, or sponsored by,
with, or on behalf of any respondent or
by any supplier or manufacturer of the
product. Also, the published report
must provide sufficient information
about the test for experts in the relevant
VerDate Sep<11>2014
17:25 Feb 27, 2018
Jkt 244001
field to assess the reliability of the
results.
Provision X mandates that
respondents acknowledge receipt of the
order, distribute the order to principals,
officers, and certain employees and
agents, and obtain signed
acknowledgments from them.
Provision XI requires that respondents
submit compliance reports to the FTC
60 days after the order’s issuance and
submit notifications when certain
events occur for 10 years.
Provision XII requires that
respondents create and retain certain
records for 10 years.
Provision XIII provides for the FTC’s
continued compliance monitoring of
respondents’ activities during the
order’s effective dates.
Provision XIV requires that
respondents notify their licensees,
monitor their highest-selling licensees’
advertising to ensure compliance with
Provisions I through III, and suspend
any licensee who makes any prohibited
claims. Respondents must terminate any
licensee who continues to make
prohibited claims. There are two limited
exceptions to the monitoring
requirement: (1) Representations during
private consultations between a licensee
and one of the licensee’s patients about
the potential safety, health benefits,
performance, efficacy, or side effects of
a covered product; and (2)
representations about the potential
safety, health benefits, performance,
efficacy, or side effects of a covered
product by a licensee who has
purchased a covered product solely for
incorporation into the licensee’s own
product and markets that product
without any involvement by
respondents.
Provision XV requires that
respondents send a notice to all
customers who purchased directly from
them TA–65MD or TA–65 Skin within
one year prior to the issuance of the
order or through a currently active
enrollment in a continuity or autoship
program.
Provision XVI provides that, with
exceptions, the order will terminate in
20 years.
The purpose of this analysis is to
facilitate public comment on the order,
and it is not intended to constitute an
official interpretation of the complaint
or order, or to modify the order’s terms
in any way.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2018–04025 Filed 2–27–18; 8:45 am]
BILLING CODE 6750–01–P
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Request for Information Regarding
Patient-Reported Outcome Measures
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Request for information.
AGENCY:
AHRQ is seeking information
submissions from the public.
Information is being solicited to inform
our work on patient-reported outcomes
(PROs). Access to information regarding
physical function PRO measure use will
assist the selection of measures for
AHRQ’s efforts to develop and
implement user-friendly technical tools
to collect and integrate PRO data in
electronic health records or other health
information technology products.
DATES: Submission must be received by
April 1, 2018.
ADDRESSES: Electronic responses are
preferred and should be addressed to
Janey.hsiao@ahrq.hhs.gov. Nonelectronic responses will also be
accepted. Please mail to: Janey Hsiao,
Agency for Healthcare Research and
Quality, 5600 Fishers Lane, Rockville,
MD 20857, Mailstop: 06E73A.
FOR FURTHER INFORMATION CONTACT:
Janey Hsiao, Health Scientist
Administrator, Center for Evidence and
Practice Improvement, Janey.hsiao@
ahrq.hhs.gov, (301) 427–1335.
SUPPLEMENTARY INFORMATION: AHRQ
plans to conduct a Challenge
Competition in Fall 2018 to develop
user-friendly technical tools to collect
and integrate patient-reported outcome
(PRO) data in electronic health records
or other health information technology
products. The technical tools will be
intended for use in ambulatory care
settings including primary care and
specialty care. For this competition,
AHRQ will choose a physical function
PRO measure as a use case for the tool
development. More information about
the Challenge Competition is available
at https://www.gpo.gov/fdsys/pkg/FR2017-12-26/pdf/2017-27663.pdf. AHRQ
will also conduct another project to
pilot test whether the specified
standards used in the Challenge
Competition can be adapted for data
collection utilizing other PRO measures
or domains. AHRQ is interested in
learning what physical function PRO
measures are being used, and about
experiences with these measures in
clinical practice. We are also interested
in methods used to collect these PROs,
including computer adaptive testing
SUMMARY:
E:\FR\FM\28FEN1.SGM
28FEN1
Federal Register / Vol. 83, No. 40 / Wednesday, February 28, 2018 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
(CAT). The information will inform
AHRQ’s decision in selecting physical
function PRO measures for the
Challenge Competition and the
subsequent pilot test.
Your contribution will be very
beneficial to AHRQ’s PRO projects. This
is a voluntary request for information,
and all costs for complying with this
request must be borne by the submitter.
This RFI is for planning purposes
only and should not be construed as a
policy, solicitation for applications, or
as an obligation on the part of the
Government to provide support for any
ideas identified in response to it. AHRQ
will use the information submitted in
response to this RFI at its discretion and
will not provide comments to any
responder’s submission. However,
responses to the RFI may be reflected in
future solicitation(s) or policies.
Respondents are advised that the
Government is under no obligation to
acknowledge receipt of the information
received or provide feedback to
respondents with respect to any
information submitted. No proprietary,
classified, confidential, or sensitive
information should be included in your
response. The Government reserves the
right to use any non-proprietary
technical information in any resultant
solicitation(s). The contents of all
submissions will be made available to
the public upon request. Materials
submitted must be publicly available or
able to be made public.
Submission Instructions
Specific questions of interest to
AHRQ include, but are not limited to:
1. What physical function PRO
measures does your health system/
practice currently use to collect PRO
data? Which PRO measures in use do
you find most useful with respect to
clinical management, quality
improvement, population health, or for
other uses?
2. What is the type of care setting
(primary care or specialty care) within
which these physical function PRO data
are collected? Are similar measures
used in other settings (e.g., acute care,
post-acute care, rehabilitation, home
care, long term care)?
3. How are the PRO data collected? Is
the PRO data collection via paper or an
electronic mechanism? Please specify
the electronic mechanism (e.g., patient
portal, tablet) and whether the
electronic mechanism is internal or
external to an electronic health records
system. Is CAT used? What is the
typical workflow for collecting PRO
data?
4. How are the PRO data used (e.g.,
patient assessment, shared decision
VerDate Sep<11>2014
17:25 Feb 27, 2018
Jkt 244001
making, quality improvement,
research?) What has been your
experience with the use of these
measures?
AHRQ is interested in all of the
questions listed above, but respondents
are welcome to address as many or as
few as they choose and to address
additional areas of interest not listed.
Submission of copies of existing
documentation or reports describing the
measure and its properties, existing data
sources, etc., is highly desirable but not
required.
Gopal Khanna,
Director.
8675
include financial holdings,
consultancies, non-financial scientific
interests, and research grants or
contracts.
To obtain a diversity of perspectives,
AHRQ particularly encourages
nominations of women, members of
minority populations, and persons with
disabilities. Interested individuals can
nominate themselves. Organizations and
individuals may nominate one or more
people qualified for membership on the
USPSTF at any time. Individuals
nominated prior to May 15, 2017, who
continue to have interest in serving on
the USPSTF should be re-nominated.
[FR Doc. 2018–04050 Filed 2–27–18; 8:45 am]
Qualification Requirements
BILLING CODE 4160–90–P
To qualify for the USPSTF and
support its mission, an applicant or
nominee should, at a minimum,
demonstrate knowledge, expertise and
national leadership in the following
areas:
1. The critical evaluation of research
published in peer-reviewed literature
and in the methods of evidence review;
2. Clinical prevention, health
promotion and primary health care; and
3. Implementation of evidence-based
recommendations in clinical practice
including at the clinician-patient level,
practice level, and health-system level.
Additionally, the Task Force benefits
from members with expertise in the
following areas:
D Public health
D Health equity and the reduction of
health disparities
D Application of science to health
policy
D Behavioral medicine
D Communication of scientific findings
to multiple audiences including
health care professionals, policy
makers and the general public.
Candidates with experience and skills
in any of these areas should highlight
them in their nomination materials.
Applicants must have no substantial
conflicts of interest, whether financial,
professional, or intellectual, that would
impair the scientific integrity of the
work of the USPSTF and must be
willing to complete regular conflict of
interest disclosures.
Applicants must have the ability to
work collaboratively with a team of
diverse professionals who support the
mission of the USPSTF. Applicants
must have adequate time to contribute
substantively to the work products of
the USPSTF.
ADDRESSES: Submit your responses
either in writing or electronically to:
Lydia Hill, ATTN: USPSTF
Nominations, Center for Evidence and
Practice Improvement, Agency for
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Solicitation for Nominations for
Members of the U.S. Preventive
Services Task Force (USPSTF)
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Solicits nominations for new
members of the USPSTF.
AGENCY:
The Agency for Healthcare
Research and Quality (AHRQ) invites
nominations of individuals qualified to
serve as members of the U.S. Preventive
Services Task Force (USPSTF).
DATES: All nominations submitted in
writing or electronically will be
considered for appointment to the
USPSTF. Nominations must be received
by May 15th of a given year to be
considered for appointment to begin in
January 2019.
SUMMARY:
Nomination Submissions
Nominations may be submitted in
writing or electronically, but should
include:
1. The applicant’s current curriculum
vitae and contact information, including
mailing address, email address, and
telephone number; and
2. A letter explaining how this
individual meets the qualification
requirements and how he or she would
contribute to the USPSTF. The letter
should also attest to the nominee’s
willingness to serve as a member of the
USPSTF.
AHRQ will later ask people under
serious consideration for USPSTF
membership to provide detailed
information that will permit evaluation
of possible significant conflicts of
interest. Such information could
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
E:\FR\FM\28FEN1.SGM
28FEN1
]]>Agencies
[Federal Register Volume 83, Number 40 (Wednesday, February 28, 2018)]
[Notices]
[Pages 8674-8675]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-04050]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Request for Information Regarding Patient-Reported Outcome
Measures
AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.
ACTION: Request for information.
-----------------------------------------------------------------------
SUMMARY: AHRQ is seeking information submissions from the public.
Information is being solicited to inform our work on patient-reported
outcomes (PROs). Access to information regarding physical function PRO
measure use will assist the selection of measures for AHRQ's efforts to
develop and implement user-friendly technical tools to collect and
integrate PRO data in electronic health records or other health
information technology products.
DATES: Submission must be received by April 1, 2018.
ADDRESSES: Electronic responses are preferred and should be addressed
to [email protected]. Non-electronic responses will also be
accepted. Please mail to: Janey Hsiao, Agency for Healthcare Research
and Quality, 5600 Fishers Lane, Rockville, MD 20857, Mailstop: 06E73A.
FOR FURTHER INFORMATION CONTACT: Janey Hsiao, Health Scientist
Administrator, Center for Evidence and Practice Improvement,
[email protected], (301) 427-1335.
SUPPLEMENTARY INFORMATION: AHRQ plans to conduct a Challenge
Competition in Fall 2018 to develop user-friendly technical tools to
collect and integrate patient-reported outcome (PRO) data in electronic
health records or other health information technology products. The
technical tools will be intended for use in ambulatory care settings
including primary care and specialty care. For this competition, AHRQ
will choose a physical function PRO measure as a use case for the tool
development. More information about the Challenge Competition is
available at https://www.gpo.gov/fdsys/pkg/FR-2017-12-26/pdf/2017-27663.pdf. AHRQ will also conduct another project to pilot test whether
the specified standards used in the Challenge Competition can be
adapted for data collection utilizing other PRO measures or domains.
AHRQ is interested in learning what physical function PRO measures are
being used, and about experiences with these measures in clinical
practice. We are also interested in methods used to collect these PROs,
including computer adaptive testing
[[Page 8675]]
(CAT). The information will inform AHRQ's decision in selecting
physical function PRO measures for the Challenge Competition and the
subsequent pilot test.
Your contribution will be very beneficial to AHRQ's PRO projects.
This is a voluntary request for information, and all costs for
complying with this request must be borne by the submitter.
This RFI is for planning purposes only and should not be construed
as a policy, solicitation for applications, or as an obligation on the
part of the Government to provide support for any ideas identified in
response to it. AHRQ will use the information submitted in response to
this RFI at its discretion and will not provide comments to any
responder's submission. However, responses to the RFI may be reflected
in future solicitation(s) or policies. Respondents are advised that the
Government is under no obligation to acknowledge receipt of the
information received or provide feedback to respondents with respect to
any information submitted. No proprietary, classified, confidential, or
sensitive information should be included in your response. The
Government reserves the right to use any non-proprietary technical
information in any resultant solicitation(s). The contents of all
submissions will be made available to the public upon request.
Materials submitted must be publicly available or able to be made
public.
Submission Instructions
Specific questions of interest to AHRQ include, but are not limited
to:
1. What physical function PRO measures does your health system/
practice currently use to collect PRO data? Which PRO measures in use
do you find most useful with respect to clinical management, quality
improvement, population health, or for other uses?
2. What is the type of care setting (primary care or specialty
care) within which these physical function PRO data are collected? Are
similar measures used in other settings (e.g., acute care, post-acute
care, rehabilitation, home care, long term care)?
3. How are the PRO data collected? Is the PRO data collection via
paper or an electronic mechanism? Please specify the electronic
mechanism (e.g., patient portal, tablet) and whether the electronic
mechanism is internal or external to an electronic health records
system. Is CAT used? What is the typical workflow for collecting PRO
data?
4. How are the PRO data used (e.g., patient assessment, shared
decision making, quality improvement, research?) What has been your
experience with the use of these measures?
AHRQ is interested in all of the questions listed above, but
respondents are welcome to address as many or as few as they choose and
to address additional areas of interest not listed. Submission of
copies of existing documentation or reports describing the measure and
its properties, existing data sources, etc., is highly desirable but
not required.
Gopal Khanna,
Director.
[FR Doc. 2018-04050 Filed 2-27-18; 8:45 am]
BILLING CODE 4160-90-P
